A449 patients. METHODS: The scale, which was translated into English from Turkish, again translated back into English by two independent translators, was applied to 32 MSDs patiets for pre-test. Non working questions applied to a target group were retested and then the scale was applied to the bulk of subjects (N 82). Cronbach's Alfa was used to assess reliability and factor analysis to assess dimensionality. The EuroQol-5D was used for concurrent validity. RESULTS: Among the patients were 15.9% ankylosing spondylitis, 6.1% rheumatoid arthritis, 24.4% osteoarthritis, 12.2% osteoporosis, 13.4% radiculitis, 9.8% fibromyalgia, 2.4% stroke, 15.9% rheumatic disease. The internal consistency coefficient (Cronbach's alpha) of SFS was 0.68. Factor analysis of the scale revealed that it was composed of three factors with Eigenvalues 1, accounting for 90.8% of the total variance. All items of the Turkish SFS had a factor load ranging from 0.40 to 0.77 There was a strong relationship between Social Functioning Scale and EuroQoL 5D. CONCLUSIONS: The Social Functioning Scale has good validity and reliability for Turkish MSDs patient.
PMS84

IMPACT OF CERTOLIZUMAB PEGOL (CZP) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL): RHEUMATOID ARTHRITIS (RA) PATIENTS APPROACH POPULATION US NORMS IN MENTAL HEALTH AND VITALITY DOMAINS
Mean changes from baseline in HRQoL were analysed in completers at Week 100; domain scores were compared with US population norms (age/gender matched). RESULTS: CZP completers reported rapid and marked improvements in HRQoL at Weeks 12 (1st assessment) and 52 that were sustained to 100 weeks. Completers originally receiving CZP 200mg MTX had mean PCS and MCS improvements of 7.2 and 8.8 points, respectively, at Week 12, 9.1 and 8.2 points at Week 52, and 10.1 and 7.7 points at Week 100; improvements were similar in patients originally receiving CZP 400 mg MTX. Improvements in RE, GH and MH were sustained following long-term OL treatment, and met or exceeded MCID in PF, RP, BP and VT, which had the largest decrements at baseline. After 100 weeks of CZP MTX, BP, VT, SF and MH scores approached or met normative values. CONCLUSIONS: CZP MTX treatment results in rapid and clinically meaningful improvements in PCS, MCS and all SF-36 domains that were sustained over 2 years. BP, VT, SF and MH approached or met age/gender matched US population norms. Comparable benefits were reported in RA patients enrolled in both CZP treatment arms.
PMS85
EQ-5D VISUAL ANALOGUE SCALE (VAS) AND UTILITY INDEX VALUES IN FRENCH WOMEN WITH A DIAGNOSIS OF POST-MENOPAUSAL OSTEOPOROSIS
Rajzbaum G 1 , Lespessailles E 2 , Gasquet I 3 , Branchoux S 4 , Cotte FE 4 1 Saint Joseph Hospital, Paris, France, 2 CHR Orleans, Orleans, France, 3 Inserm U669, Villejuif, France, 4 GlaxoSmithKline France, Marly le Roi, France OBJECTIVES: Utility, one single value of quality of life ranged from 0 to 1, is known to differ between countries and available data in French population are sparse. This study reports on the effect of different fractures sites on self-reported EQ-5D in the post-menopausal osteoporosis population. METHODS: This cross-sectional study was carried out in general population by self completion questionnaire. Eligible women were those diagnosed for osteoporosis and aged 50 years and over. Utility was assessed using the index and VAS (range: 0-100) scores of the EQ-5D. For each group, the mean EQ-5D scores are reported. Univariate analysis on EQ5D index score permitted to select covariables. As commonly used in health status studies, multivariate linear model including previous variables was performed in order to identify factors that most affected respondents' EQ-5D scores. RESULTS: Questionnaires from a total of 637 osteoporotic women were analysed. Among them, 228 already suffered a fracture. Last osteoporotic fracture sites reported were hip (N 22), vertebrae (N 45), wrist (N 80), rib (N 65), and others (N 16). Fractured women were older (mean age: 70.3 8.1 vs 67.0 7.1 years; p 0.0001), had higher BMI values (p 0.0167) than others. When adjusted for age, the index and VAS scores of the EQ-5D were both significantly different (p 0.01) between fractured (0.72 0.25; 68.3 16.46) and non fractured women (0.77 0.20; 72.3 14.82). Moreover, patient's utility significantly decreased for hip and vertebral fractures with 0.114 and 0.102, respectively (p 0.01). However, loss of utility for patient with other fractures was not significant ( 0.017; p 0.41). CONCLUSIONS: Both hip and vertebral fractures showed durable loss of utility, whereas other osteoporotic sites do not. Used for cost-utility analyses, mean QALYs of fractures for French osteoporotic population could be also calculated.
PMS86 CERTOLIZUMAB PEGOL DEMONSTRATES SIGNIFICANT IMPROVEMENTS IN THE PRODUCTIVITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PARTICULARLY IN THE HOUSEHOLD
Smolen J 1 , Purcaru O 2 , Emery P 3 1 Medical University of Vienna, Vienna, Austria, 2 UCB, Brussels, Belgium, 3 Leeds General Infirmary, Leeds, UK OBJECTIVES: The impact of rheumatoid arthritis (RA) on patients' work ability is well established. However, there is growing recognition of the impact on patients' ability to perform household duties and social activities. This evaluates the impact of certolizumab pegol (CZP) plus methotrexate (MTX) on productivity within and outside the home in patients with active RA. METHODS: In RAPID1 and 2, productivity was assessed 4-weekly from baseline using the novel validated Work Productivity Survey (WPS-RA) that measures productivity limitations due to RA on work outside the home, household work and social activities. Mean changes from baseline in missed days of household work, days with reduced household productivity, missed days of family/social/leisure activities, self-reported work absenteeism and presenteeism (work days with productivity reduced by 50%) and RA impact on productivity a 0-10 scale (10 complete interference) were compared between treatment arms using non-parametric bootstrap-t methodology. RESULTS: A total 982 and 619 patients were randomized into RAPID1, and 2, respectively. Baseline employment rates were 41.6% and 39.8%, respectively. The other patients included homemakers, retirees, those unable to work due to RA, and those unemployed for other reasons. Within each trial, treatment groups were comparable at baseline for productivity within and outside the home. In both trials, improvements in productivity within and outside the home were observed in the CZP arms as early as Week 4, and maintained until study end (RAPID1: 12 months, RAPID2: 6 months). In RAPID1, patients on CZP 200 mg MTX reported significant decreases at Week 24 in days missed of household work (mean change 4.67 vs 1.54 days/month for MTX alone) and days with reduced productivity (mean change 5.68 vs 2.85 days/month for MTX alone). Similar improvements were reported with CZP 400 mg MTX and in RAPID2. Improvements in work productivity and daily activities were reported. CONCLUSIONS: CZP improves productivity within and outside the home in RA patients.
PMS87
IMPACT OF RHEUMATOID ARTHRITIS (RA) ON WORKING CONDITIONS AND INCOME
Maurel F 1 , Fautrel B 2 , Maravic M 3 , Bardoulat I 1 , Preiss P 4 , Camara C 5 , Schadtler Law L 6 , Le Pen C 7 1 IMS Health, Puteaux, France, 2 Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 3 Hopital Leopold Bellan, Paris, France, 4 Association Française des Polyarthritiques, Paris, France, 5 Wyeth Pharmaceuticals France, Paris La Défense, France, 6 Wyeth Pharmaceuticals France, Paris La Défense Cedex, France, 7 Dauphine University, Paris, France OBJECTIVES: To investigate the work related aspects of the burden of RA for patients. METHODS: A cross-sectional survey was conducted among working age RA patients (20 to 65 years old), members of one of the RA patients' associations in France. The questionnaire was self-administered and used three validated instruments, the Health Assessment Questionnaire (HAQ), the EuroQoL-5 Dimension (EQ-5D) and the Working Productivity and Activity Impairment Questionnaire-RA (WPAI-RA). RESULTS: A total of 3494 questionnaires were mailed and 1,189 (34.0%) could
